Form 4: Seres Therapeutics Executive Sells Shares Following Vesting of Restricted Stock Units

Teresa L. Young, EVP, Chief Commercial & Strategy Officer at Seres Therapeutics, sold 735 shares of common stock after the vesting of restricted stock units.

Summary

• Teresa L. Young, an executive at Seres Therapeutics, sold 735 shares of common stock at an average price of $0.541 per share.
• This sale occurred on November 18, 2024, and was part of a pre-arranged trading plan to cover taxes related to the vesting of restricted stock units.
• Prior to the sale, Ms. Young acquired 2,656 shares through the vesting of restricted stock units on November 15, 2024.
• Following these transactions, Ms. Young directly owns 90,404 shares of Seres Therapeutics common stock and 23,907 restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. The use of a 10b5-1 plan is common to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among publicly traded companies to allow insiders to sell shares without the risk of insider trading allegations.
• The vesting schedule of the restricted stock units, with a portion vesting initially and the remainder over time, is a typical structure for equity compensation.
• The sale of shares to cover taxes upon vesting is a standard practice for executives receiving equity compensation.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small volume of shares sold.

Key Dates

Keywords

Seres Therapeutics, insider trading, stock sale, restricted stock units, Rule 10b5-1, executive compensation, MCRB